GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (HKSE:02142) » Definitions » Shares Outstanding (Basic Average)

HBM Holdings (HKSE:02142) Shares Outstanding (Basic Average) : 801.7 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is HBM Holdings Shares Outstanding (Basic Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. HBM Holdings's average basic shares outstanding for the quarter that ended in Dec. 2024 was 801.7 Mil.


HBM Holdings Shares Outstanding (Basic Average) Historical Data

The historical data trend for HBM Holdings's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings Shares Outstanding (Basic Average) Chart

HBM Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial 175.80 732.38 729.44 733.94 768.25

HBM Holdings Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 725.97 732.39 735.50 734.77 801.72

HBM Holdings Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


HBM Holdings  (HKSE:02142) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


HBM Holdings Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of HBM Holdings's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


HBM Holdings Business Description

Industry
Traded in Other Exchanges
Address
218 Xinghu Street, Suite 202, Building A3, Suzhou Industrial Park, Suzhou, CHN, 215123
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.
Executives
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Wang Jingsong 2101 Beneficial owner
Advantech Capital L.p.
Pang Kee Chan Hebert
Golden Link Investment Limited
Advantech Capital Partners Ltd.
Advantech Master Investment Limited
Astrazeneca Plc 2201 Interest of corporation controlled by you
Gic Private Limited 2102 Investment manager
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Owap Investment Pte Ltd 2101 Beneficial owner
Advantech Capital Holdings Ltd.
Jun Lian Zi Ben Guan Li Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you

HBM Holdings Headlines

No Headlines